Livzon Pharmaceutical Group stock analysis
Want to see HK:1513 full AI Analyst Report?
Livzon Pharmaceutical Group (1513) Stock Price & Analysis
1513 Stock Chart & Stats
- Day’s Range
- HKD 24.74 - HKD 25.28
- 52-Week Range
- HKD 19.80 - HKD 32.94
- Previous Close
- HKD 25.00
- Volume
- N/A
- Average Volume (3M)
- 1.38M
- Market Cap
- HKD 29.40B
- Enterprise Value
- HKD 17.84B
- Total Cash (Recent Filing)
- HKD 7.31B
- Total Debt (Recent Filing)
- HKD 4.20B
- Price to Earnings (P/E)
- 18.1
- Beta
- 0.70
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- 0.41
- Next Dividend Ex-Date
- Nov 25, 2026
- Dividend Yield
- 6.22%
Bulls Say, Bears Say
Bulls Say
Strong Profitability
Sustained gross and net margins at these levels indicate a profitable pharmaceutical portfolio with meaningful earnings retained from sales. This margin base can support research investment, commercialization and resilience over the next several quarters, provided current products remain competitive.
Positive Free Cash Flow
Strong free cash flow relative to net income shows that Livzon is converting accounting profits into internally generated funds. That provides flexibility to support product development, capital allocation and shareholder returns without relying as heavily on external financing.
Moderate Leverage
Moderate leverage and a substantial equity base provide financial stability for a pharmaceutical business operating through product and earnings cycles. The balance sheet should retain capacity to fund operations and strategic investment while limiting pressure from debt obligations.
Bears Say
Revenue Contraction
The recent revenue decline follows a period of limited growth, indicating that the company is not currently expanding its top line consistently. If this persists, weaker scale benefits could constrain future earnings growth and reduce the resources available for portfolio investment.
Earnings And Return Erosion
Falling EPS and lower returns on equity show that recent profitability has weakened relative to the capital employed. Continued deterioration would reduce the company’s ability to compound shareholder value and could signal less efficient deployment of investment across its business.
Uneven Cash Conversion
Although free cash flow remains positive, its recent decline and only moderate operating cash flow coverage indicate that cash conversion is not consistently best-in-class. Such variability can make funding for development, investment and distributions less predictable over time.
Livzon Pharmaceutical Group News
1513 FAQ
What was Livzon Pharmaceutical Group’s price range in the past 12 months?
What is Livzon Pharmaceutical Group’s market cap?
When is Livzon Pharmaceutical Group’s upcoming earnings report date?
How were Livzon Pharmaceutical Group’s earnings last quarter?
Is Livzon Pharmaceutical Group overvalued?
Does Livzon Pharmaceutical Group pay dividends?
What is Livzon Pharmaceutical Group’s EPS estimate?
How many shares outstanding does Livzon Pharmaceutical Group have?
What happened to Livzon Pharmaceutical Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Livzon Pharmaceutical Group?
What is the TipRanks Smart Score and how is it calculated?
Livzon Pharmaceutical Group Stock Smart Score
Company Description
Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Daping Liu
- Employees
- 8,878
- Website
- www.livzon.com.cn
- Address
- Headquarters Building, Zhuhai, GD, 519090, CN
Livzon Pharmaceutical Group (1513) Earnings & Revenues
1513 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |







